Quick Answer
Sonoma Pharmaceuticals, Inc. reported Net Income Loss of -$3.46 million for the year ending 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +28.5% in Net Income Loss from 2024 to 2025.
- This data is from Sonoma Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Sonoma Pharmaceuticals, Inc.'s Net Income Loss has grown by 56.5%.
- Historical annual values: Fiscal year 2025: -$3.46 million | Fiscal year 2024: -$4.84 million | Fiscal year 2023: -$5.15 million | Fiscal year 2022: -$5.09 million | Fiscal year 2021: -$3.95 million | Fiscal year 2020: -$3.31 million | Fiscal year 2019: -$11.80 million | Fiscal year 2018: -$14.33 million | Fiscal year 2017: $9.27 million | Fiscal year 2016: -$10.16 million | Fiscal year 2015: -$8.20 million | Fiscal year 2014: $3.74 million | Fiscal year 2013: -$5.43 million | Fiscal year 2012: -$7.33 million | Fiscal year 2011: -$7.95 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: